ArticleResearch and practice in thrombosis and haemostasis2023
Long-term mortality in patients with pulmonary embolism: results in a single-center registry.
Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Time Trends in Cause-Specific Mortality in Patients with Pulmonary Embolism Aged 50 Years and Older.Thrombosis and haemostasis · 2026Article
- Prognostic Value and Sex-Related Differences in Chest Pain in Patients with Acute Pulmonary Embolism: A Prospective Cohort Study Beyond Myocardial Ischemia.Journal of clinical medicine · 2026Article
- Effect of perioperative intervention based on the theory of planned behavior on preventing deep vein thrombosis after laparoscopic cholecystectomy: a retrospective study.Frontiers in surgery · 2026Article
- Role of catheter-based interventions in treating pulmonary embolism.World journal of cardiology · 2025Review
- Long-term in-hospital mortality and chronic thromboembolic pulmonary hypertension after COVID-19-associated pulmonary embolism in France: a nationwide study.ERJ open research · 2025Article
- Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein Thrombosis.Thrombosis and haemostasis · 2025Article
- Additive Value of Right Ventricular Global Longitudinal Strain to a Conventional Echocardiographic Parameter to Improve Prognostic Value in Intermediate-Risk Pulmonary Embolism.Journal of the American Heart Association · 2025Article
- Risk Factors for Short and Long-Term Mortality in Acute Pulmonary Thromboembolism: A Retrospective Study.International journal of general medicine · 2025Article
- Role of Transcatheter Treatment in Intermediate-to High-risk Pulmonary Embolism.Interventional cardiology (London, England) · 2025Review
- D-dimer/high sensitive troponin I ratio is useful in predicting in-hospital mortality in pulmonary embolism patients.Irish journal of medical science · 2024Article
- Clinical Profile and Outcomes of Pulmonary Embolism in Central Iran: A Retrospective Cohort Study.Archives of Iranian medicine · 2024Article
- Risk Factors and Outcomes of Acute Pulmonary Embolism in African Patients: A Systematic Review.Cureus · 2024Review
- Mortality rate and factors associated with in-hospital mortality in patients hospitalized with pulmonary embolism in Germany.Journal of thrombosis and thrombolysis · 2024Article
- Evolution of Pulmonary Embolism Response Teams in the United States: A Review of the Literature.Journal of clinical medicine · 2024Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While numerous studies have investigated short-term outcomes after pulmonary embolism (PE), long-term mortality remains insufficiently studied. Objectives: To investigate long-term outcomes in an unselected cohort of patients with PE. Methods: A total of 896 consecutive patients with PE enrolled in a single-center registry between May 2005 and December 2017 were followed up for up to 14 years. The observed mortality rate was compared with the expected rate in the general population. Results: The total follow-up time was 3908 patient-years (median, 3.1 years). The 1- and 5-year mortality rates were 19.7% (95% CI, 17.2%-22.4%) and 37.1% (95% CI, 33.6%-40.5%), respectively. The most frequent causes of death were cancer (28.5%), PE (19.4%), infections (13.9%), and cardiovascular events (11.6%). Late mortality (after >30 days) was more frequent than expected in the general population, a finding that was consistent in patients without cancer (the 5-year standardized mortality ratios were 2.77 [95% CI, 2.41-3.16] and 1.80 [95% CI, 1.50-2.14], respectively). Active cancer was the strongest risk factor for death between 30 days and 3 years (hazard ratio [HR], 6.51; 95% CI, 4.67-9.08) but was not associated with later mortality. Death after >3 years was predicted by age (HR, 1.86; 95% CI, 1.51-2.29 per decade), chronic heart failure (HR, 1.66; 95% CI, 1.02-2.70), and anemia (HR, 1.62; 95% CI, 1.09-2.41). Conclusion: The risk of mortality in patients with PE remained elevated compared with that in the general population throughout the follow-up period. The main driver of long-term mortality during the first 3 years was cancer. After that, mortality was predicted by age, chronic heart failure, and anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.